Chandra Rampalli Viswa, Prabhuji M L Venkatesh, Roopa D Adinarayana, Ravirajan Sandhya, Kishore Hadal C
Department of Periodontics, Krishnadevaraya College of Dental Sciences, Hunasamaranahalli, Yelahanka, Bangalore, India.
Oral Health Prev Dent. 2007;5(4):327-36.
The aim of the present study was to compare the effect of systemically administered lycopene (LycoRed) as a monotherapy and as an adjunct to scaling and root planing in gingivitis patients.
Twenty systemically healthy patients showing clinical signs of gingivitis were involved in a randomised, double-blind, parallel, split-mouth study. The subjects were randomly distributed between the two treatment groups: experimental group (n = 10), 8 mg lycopene/day for 2 weeks; and controls (n = 10), placebo for 2 weeks. Quadrant allocation within each group was randomised with two quadrants treated with oral prophylaxis (OP) and two quadrants not receiving any form of treatment (non-OP). Bleeding index (SBI) and non-invasive measures of plaque (PI) and gingivitis (GI) were assessed at baseline, 1 and 2 weeks. Salivary uric acid levels were also measured.
All the treatment groups demonstrated statistically significant reductions in the GI, SBI and PI. Treatment with OP-lycopene resulted in a statistically significant decrease in GI when compared with OP-placebo (p < 0.05) and non-OP-placebo (p < 0.01). Treatment with non-OP-lycopene resulted in a statistically significant decrease in GI when compared with non-OP-placebo (p < 0.01). The OP-lycopene group showed a statistically significant reduction in SBI values when compared with the non-OP-lycopene group (p < 0.05) and the non-OP-placebo group (p < 0.001). There was a strong negative correlation between the salivary uric acid levels and the percentage reduction in GI at 1 and 2 weeks in the OP-lycopene group (r = -0.852 and -0.802 respectively) and in the non-OP-lycopene group (r = -0.640 and -0.580 respectively).
The results presented in this study suggest that lycopene shows great promise as a treatment modality in gingivitis. The possibility of obtaining an additive effect by combining routine oral prophylaxis with lycopene is also an exciting possibility, which deserves further study.
本研究旨在比较全身给予番茄红素（LycoRed）作为单一疗法以及作为龈炎患者龈上洁治和根面平整辅助治疗的效果。
20名有龈炎临床体征的全身健康患者参与了一项随机、双盲、平行、分口研究。受试者被随机分配到两个治疗组：实验组（n = 10），每天服用8毫克番茄红素，持续2周；对照组（n = 10），服用安慰剂，持续2周。每组内象限分配是随机的，两个象限接受口腔预防治疗（OP），两个象限不接受任何形式的治疗（非OP）。在基线、1周和2周时评估出血指数（SBI）以及菌斑（PI）和龈炎（GI）的非侵入性测量指标。还测量了唾液尿酸水平。
所有治疗组的GI、SBI和PI均有统计学意义的降低。与OP - 安慰剂组（p < 0.05）和非OP - 安慰剂组（p < 0.01）相比，OP - 番茄红素治疗导致GI有统计学意义的降低。与非OP - 安慰剂组相比，非OP - 番茄红素治疗导致GI有统计学意义的降低（p < 0.01）。与非OP - 番茄红素组（p < 0.05）和非OP - 安慰剂组（p < 0.001）相比，OP - 番茄红素组的SBI值有统计学意义的降低。在OP - 番茄红素组（分别为r = -0.852和 -0.802）和非OP - 番茄红素组（分别为r = -0.640和 -0.580）中，1周和2周时唾液尿酸水平与GI降低百分比之间存在强负相关。
本研究结果表明，番茄红素作为龈炎的一种治疗方式具有很大前景。将常规口腔预防与番茄红素联合使用获得相加效应的可能性也是一个令人兴奋的可能性，值得进一步研究。
